archive-fr.com » FR » C » CNG.FR

Total: 170

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CNG - Programmes
    inadequate and we do not have sufficient tools to predict disease progression or response to current or future therapies Our consortium Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling AirPROM brings together the existing clinical consortia EvA FP7 U BIOPRED IMI and BTS Severe Asthma and expertise in physiology radiology image analysis bioengineering data harmonization data security and ethics computational modelling and systems biology We shall develop an integrated multi scale model building upon existing models This airway model will be comprised of an integrated micro scale and macro scale airway model informed and validated by omic data and ex vivo models at the genome transcriptome cell tissue scale and by CT and functional MRI imaging coupled to detailed physiology at the tissue organ scale utilising Europe s largest airway disease cohort Validation will be undertaken cross sectionally following interventions and after longitudinal follow up to incorporate both spatial and temporal dimensions AirPROM has a comprehensive data management platform and a well developed ethico legal framework Critically AirPROM has an extensive exploitation plan involving at its inception and throughout its evolution those that will develop and use the technologies emerging from this project AirPROM therefore will bridge the critical gaps in our clinical management of airways disease by providing validated models to predict disease progression and response to treatment and the platform to translate these patient specific tools so as to pave the way to improved personalised management of airways disease Participants THE UNIVERSITY OF NOTTINGHAM NOTTINGHAM UNITED KINGDOM HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH NEUHERBERG DEUTSCHLAND COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES PARIS 15 FRANCE KAROLINSKA INSTITUTET STOCKHOLM SVERIGE ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM AMSTERDAM NEDERLAND THE UNIVERSITY OF WARWICK COVENTRY UNITED KINGDOM UNIVERSITE DE LA MEDITERRANEE D

    Original URL path: http://www.cng.fr/fr/projects/fp7_airprom.html (2016-01-29)
    Open archived version from archive


  • CNG - Programmes
    OF EXETER Northcote House The Queen s Drive EXETER UNITED KINGDOM Web site http www ceed3 org Project description CEED3 Collaborative European Effort to Develop Diabetes Diagnostics has as its central objective the development of diagnostic tools to differentiate specific subgroups of diabetic patients to allow individualization of patient care CEED3 will achieve this by integrating basic science findings from animal models cell studies and large scale genetic studies with clinical observations and testing of patients phenotype The development of diabetes diagnostic tools will involve a clearly defined process of discovery of potential novel genetic and non genetic biomarkers validation within test and population based data samples development of a clinical application and then dissemination of this application The areas of focus for the diabetes diagnostics will be three areas where there is potential for considerable improvement in care and reduction in the burden of diabetes the identification of patients with specific subgroups of monogenic diabetes the identification of non diabetic and diabetic subjects with initial pancreatic beta cell dysfunction at high risk of rapidly deteriorating glycaemia and the detection of diabetic patients at increased risk of vascular complications For each of these patient groups the identification of the subgroups

    Original URL path: http://www.cng.fr/fr/projects/fp7_ceed3.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    The mission of CHeartED is to identify genetic and environmental pathways that can be modified with the goal of reducing preventable CVM incidence Epidemiological studies have shown that the stress of maternal hypo or hyperglycemia increases the incidence of CVM We plan a genetic association study in individuals with and without CVM born to diabetic mothers to test whether genetic variants are associated with CVM A similar study without prior risk hypothesis addresses tetralogy of Fallot a CVM which requires surgery in early life These studies will reveal common genetic variants associated with CVM and thus add to existing knowledge on the aetiology of CVM Moreover the identification of genetic factors that differ in the context of maternal diabetes will disclose any associations in genetic pathways influenced by environmental factors RNA expression studies in the mouse to identify new genes and pathways involved in outflow tract malformations and maternal diabetes associated with CVM will complement the human studies Finally we will develop a 3D atlas of gene expression patterns and cardiac morphology at key developmental stages that will serve as a morphological framework Central to our proposal is the development of a bioinformatics tool complemented by an open access Wiki based database The bioinformatics tool will combine the sequence data and expression data generated by the human and mouse studies with morphology and literature to prioritize genes and generate hypotheses The Wiki which will contain existing and new genetic and environmental knowledge on heart development will be an aid for many groups working on cardiovascular development and a novel means of disseminating our findings In a major effort to tackle the underlying biological and genetic questions our project has formulated four work themes bringing together existing and novel knowledge on the environment and its interaction with genetic factors in causing

    Original URL path: http://www.cng.fr/fr/projects/fp7_chearted.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    GENOMIC BANK INFRAQTL MADO Autres programmes franco japonaise franco croate PHENOGENE EFRAIM Mechanisms of early protective exposures on allergy development Coordinator Contact Person VON MUTIUS Erika Professor Tel 49 8951602709 Fax 49 8951604452 Email Contact Organisation LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN Geschwister Scholl Platz 1 MUENCHEN GERMANY Web site http www efraim online com Project description Allergy has developed into a major health concern in Europe Allergic diseases can currently be managed effectively but not cured The onset of allergies stars early in life and there is increasing evidence that exogenous factors affecting the incidence of these illnesses exert their effect early in life in part even prenatally The highly interdisciplinary EFRAIM project will prospectively investigate the main protective factors in early life influencing the development of allergies in birth cohorts conducted in allergy protective environments in five European countries These birth cohorts have been enrolling over 1 000 children and have collected detailed information on the onset of allergic illnesses objective measures of allergies and a vast amount of information about a number of environmental exposures Large biobanks with a variety of biological samples have been established In the EFRAIM project particular attention will be given to the potential role

    Original URL path: http://www.cng.fr/fr/projects/fp7_efraim.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    description The objective of this project is the integration of world class high throughput sequencing and genotyping facilities that will provide sequencing and genotyping technologies and data analysis methodologies to the scientific community The European Sequencing and Genotyping Infrastructure ESGI will enable external users to generate data rapidly and to acquire knowledge efficiently By providing access to the ESGI facilities in order to benefit from the sequencing and genotyping technologies there will be an outreach and sustainable impact for the scientific community in the area of biological and medical research to generate new knowledge The ESGI will optimise European research programs and foster transnational collaborations In general the ESGI will defragment and thereby strengthen the European research capacities in genetics and genomics and improve the knowledge transfer from large genomics centres among themselves and to external expert groups or scientists who are focusing on specific research questions Our aim is to apply and improve new high throughput nucleic acids analysis technologies for a broad range of genetic and systems biology studies using well phenotyped samples for example those derived from standardised European biobanks and animal facilities In particular massively parallel sequencing technologies are essential components of modern biomedical research and

    Original URL path: http://www.cng.fr/fr/projects/fp7_esgi.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    CENTRUM FUER MOLEKULARE MEDIZIN Robert Roessle Strasse 10 BERLIN DEUTSCHLAND Web site http www mdc berlin de Objective Genetic studies in model organisms and humans including human genome wide association studies have pinpointed genomic regions that contribute susceptibility to common disease However to date these data have provided limited insights into the genes molecular pathways and mechanisms underlying disease patho physiology The EU FP6 Euratools consortium has been a remarkable success that established significant research collaborations expertise and infrastructure in the EU making a major contribution to the rat focus issue of Nature Genetics Volume 40 May 2008 which featured six papers from the consortium These successes underpin the current project in which we will use state of the art and emerging large scale technologies and advanced computation in an expanded multi disciplinary approach to identify gene networks and genomic mechanisms underlying common diseases We will use the rat as a model system to identify the major functional pathways underlying human inflammatory cardiovascular and metabolic and behavioral disorders Our consortium brings together world class investigators who will use next generation sequencing technologies to generate genomic transcriptomic and epigenomic datasets To this we will add cutting edge quantitative metabonomic and proteomic datasets to give significant depth of coverage at multiple levels across pathophysiological phenotypes These datasets will be gathered annotated and integrated in relational and dynamic models that will be used in comparative analyses to understand human gene function at the level of the molecule cell tissue and organism These studies will lead to new insights into disease mechanisms through an integrative cross disciplinary approach to understanding large scale functional genomic datasets in rats and humans Participants RIJKSUNIVERSITEIT GRONINGEN GRONINGEN NEDERLAND THE UNIVERSITY OF EDINBURGH EDINBURGH UNITED KINGDOM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM PARIS FRANCE

    Original URL path: http://www.cng.fr/fr/projects/fp7_euratrans.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    Coordinator Contact Person Françoise CARRE Dr Tel 33 169081064 Fax 33 164501157 Email Contact Organisation COMMISSARIAT ENERGIE ATOMIQUE CEA RUE LEBLANC PARIS 15 FRANCE Web site http www cea fr Objective CEA is convinced that the ability of research institutes to offer attractive working conditions and career opportunities to researchers is a key factor in meeting the challenge of maintaining and boosting Europe s scientific and economic competitiveness Thus thanks to the European Commission cofunding CEA would like to develop a centralised programme dedicated to researchers transnational mobility and based on open merit competition and international peer review This programme called Eurotalents programme will aim at increasing the mobility of scientists and at offering a boost in their career thanks to the access to new research capacities Eurotalents will open world class laboratories within CEA and abroad to researchers having an excellent scientific experience and wanting to broader their career via a research project in the scientific topic s of their choice within CEA well known domains of expertise Energy environment and climate change Life sciences and biotechnology Nanosciences and nanotechnologies Science and technology of high performance computing High energy physics and physics of the universe Eurotalents will thus offer

    Original URL path: http://www.cng.fr/fr/projects/fp7_eurotalents.html (2016-01-29)
    Open archived version from archive

  • CNG - Programmes
    3022 Fax 49 893187 3866 Email Contact Organisation HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHESFORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT GMBH Ingolstaedter Landstrasse MUNCHEN GERMANY Web site http www eva copd eu Project description The project objectives are based upon the underlying concept that COPD is characterised by emphysema and airway disease inflammation and thickening of the bronchial wall both of which lead to airway obstruction with reduced FEV These two features coexist in most patients but some patients present with either emphysema or airway disease The aim of the project is to identify markers specific to emphysema and airway disease in COPD The hypothesis of the EvA project is that the mechanisms leading to these pathologies are distinctive with regard to the type of inflammatory response and in terms of genetic predisposition The differences in pathogenesis for emphysema and inflammatory airway disease mean that the two forms of COPD are linked to different markers at the DNA RNA and protein level What methods will be used in the research By using computed tomography scans to select patients with either emphysema or airway disease the consortium will obtain material from the lung leukocytes bronchial cells and blood leukocytes and analyse elements of gene expression SNP array transcriptome Data analysis will be carried out for emphysema versus airway disease and also versus a control cohort leading to the identification of markers specifically linked to either emphysema or air way disease The markers will be elements involved in a differential pathogene sis for the different disease processes in COPD and can therefore be used for diagnostic approaches and as therapeutic targets Who will be involved The project brings together 13 partners from nine European countries and includes 10 clinical centres that identify and sample selected patients one centre for image analysis and two centres that perform

    Original URL path: http://www.cng.fr/fr/projects/fp7_eva.html (2016-01-29)
    Open archived version from archive



  •